European CHMP issues negative opinion for pexidartinib (Turalio) in treatment of tenosynovial giant cell tumour

The main study found that tumours shrank, but there was only a small improvement in symptoms (pain and ability to use the joint). There was also serious concern about unpredictable, potentially life-threatening side effects on the liver.


European Medicines Agency